An observational study in Internal Jugular Vein, Inferior Vena Cava and Collapsibility Indices, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Cairo University · Observational
This study aimed to compare between internal jugular vein and inferior vena cava collapsibility indices as a guidance of fluid responsiveness in septic shock cancer patients.
Sepsis is a life-threatening organ dysfunction due to a dysregulated host response to infection. Most common infection is bacterial but it may be viral, fungal or protozoal. Risk factors include weak immune system, old age, malignancy, and burn.
Septic shock is defined as a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities substantially increase mortality.
During spontaneous inspiration, negative intrathoracic pressure increases venous flow to the heart and reduces the inferior vena cava (IVC) diameter. At end expiration, the intrathoracic pressure increases to zero, decreasing the venous return and maximizing the IVC diameter. This has been defined as collapsibility index (CI).
Inferior vena cava may be difficult to be assessed by ultrasonography in patients with morbid obesity, abdominal distension, pregnancy and surgical drains. While the internal jugular vein (IJV) is easily accessible.
The collapsibility index of the inferior vena cava (cIVC) has potential for predicting fluid responsiveness in spontaneously breathing patients.
890 studies on the registry are indexed under Shock, Septic; 210 are open to participants now.
This study's enrollment of 106 is close to the median of 100 across 309 observational studies indexed under Shock, Septic.
Browse Shock, Septic studies →Cairo University is the lead sponsor of 4,907 studies on the registry; 1,445 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Prospective cohort study was conducted on adult cancer patients from Intensive care unit at National Cancer Institute Cairo University recently diagnosed with septic shock, spontaneously breathing and matching the inclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cancer patients with septic shock
Device: Ultrasonographic assessment of internal jugular vein (IJV) collapsibility · Device: Ultrasonographic assessment of inferior vena cava (IVC) collapsibility
Ultrasonography was used to measure the maximum and minimum anteroposterior diameters of the internal jugular vein (IJV) during a respiratory cycle, using linear and phased-array probes, respectively. The collapsibility index will be calculated as (maximum diameter - minimum diameter)/maximum diameter.
Ultrasonography was used to measure the maximum and minimum anteroposterior diameters of the inferior vena cava (IVC) during a respiratory cycle, using linear and phased-array probes, respectively. The collapsibility index will be calculated as (maximum diameter - minimum diameter)/maximum diameter.
Assessment of Internal Jugular Vein Collapsibility Index
The area under the receiver operating characteristic (ROC) curve was calculated to evaluate the ability of the baseline internal jugular vein collapsibility index to predict fluid responsiveness following intravenous administration of 500 mL of 0.9% sodium chloride over 10 minutes. The collapsibility index was calculated as (maximum diameter - minimum diameter)/maximum diameter using ultrasonographic measurements during a respiratory cycle.
Time frame: After completion of the 10-minute fluid challenge
Assessment of Inferior Vena Cava Collapsibility Index
The area under the receiver operating characteristic (ROC) curve was calculated to evaluate the ability of the baseline inferior vena cava collapsibility index to predict fluid responsiveness after the fluid challenge. The index was calculated as (maximum diameter - minimum diameter)/maximum diameter using ultrasonography.
Time frame: After completion of the 10-minute fluid challenge
Change in Mean Arterial Pressure
Change in mean arterial pressure, measured in mmHg, calculated as the post-fluid-challenge value minus the baseline value.
Time frame: After completion of the 10-minute fluid challenge
Change in Heart Rate
Change in heart rate, measured in beats per minute, calculated as the post-fluid-challenge value minus the baseline value.
Time frame: After completion of the 10-minute fluid challenge
Change in Cardiac Output
Change in cardiac output, measured in L/min using electrical cardiometry, calculated as the post-fluid-challenge value minus the baseline value.
Time frame: After completion of the 10-minute fluid challenge
Change in Pulse Pressure
Change in pulse pressure, measured in mmHg as systolic blood pressure minus diastolic blood pressure, calculated as the post-fluid-challenge value minus the baseline value.
Time frame: After completion of the 10-minute fluid challenge
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Dec 2024, 17 months.
Of 137 non-industry observational studies under Shock, Septic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 54. This study's 17 months is below that.
Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 13 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.